NVCT compared with PGEN: revenue, margins and what each company keeps, and the suppliers and customers both name

NVCTNuvectis Pharma, Inc.

Mkt capRevenueRevenue

PGENPrecigen, Inc.

Mkt capRevenueRevenue

Compare

NVCTNuvectis Pharma, Inc.

PGENPrecigen, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

NVCT: latest quarter not drawable.Method ›

Price

rebased to 0%

NVCT, solidPGEN, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NVCT 4

—CRT Pioneer Fundunlistedsupplier

—ICRunlistedsupplier

—University of Edinburghunlistedsupplier

—UoEunlistedsupplier

Shared 0

No shared counterparties.

Only PGEN 8

PTCTPTC Therapeuticscustomer

—University of Texas MD Anderson Cancer Centerunlistedsupplier

—Eversanaunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

National Cancer Institute (NCI)

unlistedsupplier

4 more · PGEN chain ›

NVCTNuvectis Pharma, Inc.

19.12· pre 19.32· delayed

Mkt cap$630.1MRevenue—Revenue—

PGENPrecigen, Inc.

5.25· pre 5.29· delayed

Pre-marketNov 4 '26delayed

Mkt cap$1.9BRevenue$55MQ2 FY26Revenue$10MFY25

Compare

Pre-marketNov 4 '26delayed

NVCTNuvectis Pharma, Inc.

PGENPrecigen, Inc.

19.12pre 19.32delayed

Price

5.25pre 5.29delayed

$630.1M

Mkt cap

$1.9B

—

Revenue

$55MQ2 FY26

—

Revenue

$10MFY25

NVCT19.12vsPGEN5.25Pre-marketNov 4 '26delayed